On Tuesday, Moderna became the youngest pharmaceutical company to file with the U.S. Food and Drug Administration for full approval of its coronavirus vaccine for use in people aged 18 and over.
Last month, Pfizer and BioNTech filed with the agency for full approval of their vaccine for use in people aged 16 and over.
"We look forward to working with the F.D.A. and will continue to submit data from our Phase 3 study and complete the ongoing filing, ”said Stéphane Bancel, CEO of Moderna, in a statement.
Moderna's emergency vaccine was approved in December, and by Sunday more than 151 million doses had been administered in the United States, according to the Centers for Disease Control and Prevention.
"I think there are a lot of people who have been on the fence worrying about moving too quickly and possible side effects," said Dr. William Schaffner, National Infectious Disease Foundation medical director and vaccine expert. "But those concerns will be allayed as more friends and acquaintances celebrate that they will be vaccinated."
Jan Hoffman contributed to the coverage.